ClinicalTrials.Veeva

Menu
J

Juno Research, Inc. | Southwest Site, Houston, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Metformin
LY3298176
Tirzepatide
LY3502970
Orforglipron
Retatrutide
Olezarsen
Lorundrostat
Dapagliflozin
LY3437943

Parent organization

This site is a part of Juno Research, Inc.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

25 of 62 total trials

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to...

Active, not recruiting
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388...

Enrolling
Type 2 Diabetes Mellitus (T2DM)
Overweight or Obese
Drug: CT-388
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Enrolling
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropath...

Enrolling
Diabetic Peripheral Neuropathy
Drug: LY3556050
Drug: Placebo

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in p...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Dapagliflozin

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than t...

Enrolling
Obesity
Drug: Mibavademab-Placebo
Drug: Tirzepatide-Placebo

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling
Hypothyroidism
Drug: Levothyroxine
Drug: Armour Thyroid

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This study is open to adults who are at least 18 years old and have* a body mass index (BMI) of 30 kg/m² or more, or* a BMI of 27 kg/m² or more and a...

Active, not recruiting
Obesity
Drug: survodutide
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Enrolling
Type 2 Diabetes
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and...

Enrolling
Diabetes Mellitus, Type 2
Drug: Retatrutide
Drug: Semaglutide

Trial sponsors

Lilly logo
Ionis Pharmaceuticals logo
Pfizer logo
M
Arrowhead Pharmaceuticals logo
AstraZeneca logo
Boehringer Ingelheim logo
I
Shionogi logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems